Abonnement for 2 €

Sikre fra 2 euro

Institutional-grade intelligence for professional investors

LIVE

•Real-time feeds•Global markets•24/7 coverage

Entrada Therapeutics Aktie News & Pressemeldungen

Entrada Therapeutics Eulerpool Nyheter

Entrada Therapeutics Aksje Nyheter

Entrada Therapeutics blir fulgt av mange journalister og investorer over hele verden. De nyeste Entrada Therapeutics nyhetene presenterer vi her.

·
SeekingAlpha
Tracking Baker Brothers Portfolio - Q1 2025 Update
·
Yahoo
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
·
Yahoo
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
·
Yahoo
Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU
·
Yahoo
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
·
Yahoo
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results
·
Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
·
Yahoo
Entrada Therapeutics Reports First Quarter 2025 Financial Results
·
Yahoo
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
·
Yahoo
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

1

2

1

2

Entrada Therapeutics Aksje Pressemeldinger

Entrada Therapeutics publiserer regelmessig meldinger som er relevante for investorer på selskapets nettside.

Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Sikre deg fra 2 euro

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan